Peptides - Compound guides
DSIP (Delta Sleep-Inducing Peptide)
DSIP is a peptide isolated from rabbit brain in the 1970s whose proposed role in sleep regulation remains disputed and poorly replicated.
Delta sleep-inducing peptide, almost always shortened to DSIP, is a nine-amino-acid peptide first described in the mid-1970s. The origin story is unusual and worth knowing, because it shapes everything that followed. Swiss researchers took blood from rabbits whose brains were being electrically stimulated in a way that produced slow-wave sleep patterns, transferred material from that blood into other rabbits, and reported that the recipients showed increased delta-wave activity - the slow brain rhythm characteristic of deep sleep. From that transferred material they isolated and sequenced a peptide, and named it after the effect they believed they had observed.
That name has done a great deal of work ever since. It is a label describing a hypothesis from 1976, not a confirmed function, and half a century later the hypothesis has not been settled. DSIP is found in various tissues and its distribution does not obviously match what you would expect of a dedicated sleep regulator. Some researchers question whether it functions as a genuine endogenous sleep-regulating molecule at all. Online it is nonetheless sold and discussed as though the question were closed, which it is not.
How it is thought to work
The proposals here are genuinely disputed, more so than for most compounds covered on this site, and none is established.
The original proposal was straightforward: DSIP circulates as a signalling molecule that promotes slow-wave sleep. Subsequent work struggled to support this cleanly. Attempts to reproduce the original sleep findings gave inconsistent results, with some laboratories reporting effects, others reporting none, and some reporting effects in the opposite direction depending on species, timing and measurement method. Efforts to identify a specific receptor for DSIP have not produced a clearly characterised target, which is a significant gap - most well-understood signalling peptides have an identified receptor and a traceable downstream pathway.
Alternative proposals have accumulated over the years, including roles in stress hormone regulation, in the body's daily circadian timing signals, and in interactions with opioid signalling. These have been suggested rather than demonstrated. Taken together, the picture is not one of a molecule with a well-mapped mechanism and unresolved clinical questions; it is one of a molecule whose basic biological role is still an open question after fifty years of intermittent attention.
What the research actually shows
DSIP sits at a preclinical rung of the evidence ladder. The bulk of the literature is animal work from the 1970s and 1980s. Human studies exist but are few, very small, decades old, and inconsistent with one another. The research is scattered across several groups working at a time when sleep measurement, statistical practice and trial reporting were all far less rigorous than they are today. Much of the more enthusiastic later work comes from a narrow set of research traditions and has not been independently repeated with modern polysomnography and pre-registered analysis plans.
Independent replication is the whole issue here. Sleep research is unusually prone to producing results that vanish on closer inspection: sleep varies enormously between individuals and between nights, laboratory settings themselves disturb it, expectation strongly influences how people report sleeping, and the number of ways to slice sleep-stage data means an analysis can produce a positive-looking finding almost by accident. A finding that survives only in the laboratory that first reported it, using methods that laboratory chose, is weak evidence by design. DSIP has never accumulated the body of independent, modern, adequately powered replications that would move it up the ladder. When a proposed effect has failed to consolidate over five decades, the most reasonable interpretation is not that the world has overlooked it, but that the original effect was smaller, less reliable, or more measurement-dependent than it first appeared.
Where the evidence stops
- Whether DSIP is a genuine endogenous sleep-regulating molecule remains disputed among researchers.
- No specific, well-characterised receptor or downstream pathway has been established.
- The original sleep findings have not been consistently reproduced across laboratories and species.
- Human data is minimal, decades old, small in scale and conducted before modern sleep-measurement and reporting standards.
- Long-term safety in humans has not been studied in any meaningful way.
- As an unregulated research chemical, identity, purity and sterility of available material are unverified.
Legal and regulatory status
DSIP is not an approved medicine anywhere in the United Kingdom, the European Union or the United States. Unlike Semax and Selank, it does not hold a medicines registration in Russia or elsewhere either - it has never completed a regulatory approval process in any major jurisdiction. It is sold as a research chemical, which means it sits entirely outside the medicines quality framework: no batch testing to pharmacopoeial standards, no sterility assurance, no regulated manufacturing inspection, no pharmacovigilance system collecting reports of harm.
Products of this kind are typically labelled "research use only". That phrase means what it says - the material is not approved for human use. It is a statement about regulatory status, not a disclaimer to be read past on the way to using something.
This lesson is educational content only and is not medical advice. DSIP is not an approved medicine in the UK and nothing here is a recommendation to use it. Persistent sleep problems have real and treatable causes, and they belong with a qualified healthcare professional.
Neuro and sleep compounds
Start with the overview: How research peptides are grouped into families
Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.
